

Powel H Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4022775/publications.pdf>

Version: 2024-02-01

29
papers

1,119
citations

411340

20
h-index

536525

29
g-index

30
all docs

30
docs citations

30
times ranked

2478
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	9.4	31
2	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. <i>Gut</i> , 2021, 70, 555-566.	6.1	37
3	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021, 26, 71-82.	0.8	4
4	Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). <i>Cancer Prevention Research</i> , 2021, 14, 325-336.	0.7	12
5	S318â€fOptimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. <i>American Journal of Gastroenterology</i> , 2021, 116, S138-S138.	0.2	0
6	SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis. <i>Molecular Cancer Research</i> , 2020, 18, 1825-1838.	1.5	38
7	PI4KIIIÎ² is a therapeutic target in chromosome 1qâ€“amplified lung adenocarcinoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	41
8	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020, 130, 958-973.	3.9	53
9	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). <i>Cancer Prevention Research</i> , 2019, 12, 481-490.	0.7	14
10	Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2136-2142.	3.2	112
11	Natural product Î²-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy. <i>DNA Repair</i> , 2017, 60, 89-101.	1.3	9
12	Molecularly targeted therapies for p53-mutant cancers. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 4171-4187.	2.4	72
13	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 441-454.	1.1	26
14	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. <i>Cancer Research</i> , 2016, 76, 1942-1953.	0.4	77
15	Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved. <i>Oncologist</i> , 2016, 21, 4-6.	1.9	1
16	The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. <i>Oncotarget</i> , 2016, 7, 13106-13121.	0.8	63
17	TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3216-25.	3.3	68
18	Molecular cancer prevention: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 345-383.	157.7	83

#	ARTICLE	IF	CITATIONS
19	Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 211-220.	1.1	90
20	Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 96-109.	0.5	36
21	Revealing targeted therapeutic opportunities in triple-negative breast cancers: A new strategy. <i>Cell Cycle</i> , 2013, 12, 2705-2706.	1.3	11
22	The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 487-500.	1.1	30
23	SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). <i>Breast Cancer Research and Treatment</i> , 2012, 134, 101-115.	1.1	47
24	The retinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 667-677.	1.1	34
25	Retinoid-induced Expression of IGFBP-6 Requires RAR β -dependent Permissive Cooperation of Retinoid Receptors and AP-1. <i>Journal of Biological Chemistry</i> , 2009, 284, 345-353.	1.6	26
26	Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor α -Selective Retinoid. <i>Cancer Prevention Research</i> , 2008, 1, 208-214.	0.7	33
27	Risk Assessment: Controversies and Management of Moderate- to High-Risk Individuals. <i>Breast Journal</i> , 2005, 11, S11-S19.	0.4	13
28	AP-1 blockade inhibits the growth of normal and malignant breast cells. <i>Oncogene</i> , 2001, 20, 2771-2780.	2.6	53
29	RESPONSE: Re: Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost. <i>Journal of the National Cancer Institute</i> , 2000, 92, 658-658.	3.0	3